

Figure 1






Figure 2

LifeMasters

LifeMasters® CAD Program – Risk Assessment Survey

Section 1 – Patient/Physician Information

Please complete the following

Patient Name:		
What is the name of your physician:	Phone number if available:	
Is your physician a cardiologist:	<input type="checkbox"/> Yes	<input type="checkbox"/> No

Section II – Predictors of Coronary Artery Disease Risk

Please complete the following

What is your LDL cholesterol level ("bad" cholesterol) ?	<input type="checkbox"/> More than 100 mg/dL	<input type="checkbox"/> 100 mg/dL or less
What is your HDL cholesterol level ("good" cholesterol)?	<input type="checkbox"/> More than 35 mg/dL	<input type="checkbox"/> 35 mg/dL or less
What is your triglycerides level?	<input type="checkbox"/> More than 200 mg/dL	<input type="checkbox"/> 200 mg/dL or less
Is your blood pressure 130/80 or higher?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Do you currently smoke cigarettes?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Do you have diabetes or do you take medicines to control your blood glucose?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Has your doctor told that you have problems with the arteries (blood vessels) in your heart?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Have you ever had a heart attack?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Has your doctor told you that you have an enlarged heart or heart failure?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Have you been admitted to the hospital or visited the emergency department in the previous 12 months for a heart problem?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Did a first-degree relative (father, mother, brother, sister, son or daughter) have a heart attack before the age of 55 years?	<input type="checkbox"/> Yes	<input type="checkbox"/> No

Figure 3

Dear [Healthcare Provider]:

<<customer>> is pleased to introduce the LifeMasters® Coronary Artery Disease (CAD) Primary Prevention program, a disease management intervention for <<customer>> patients. This innovative program was established to reduce the incidence of angina, myocardial infarctions and strokes in patients at high risk for coronary artery disease (CAD). LifeMasters' goal is to identify individuals who are at high risk for CAD and then support physicians in their care management of these patients. A high risk patient for CAD is defined by the American Heart Association as any individual with two or more cardiovascular risk factors (hypertension, hyperlipidemia, positive family history for CAD, current smoker, etc.) or having diabetes. Once a high risk patient is identified through an evidence-based risk assessment survey, the patient is enrolled in the following support program that facilitates the "best practice" management of that patient's CAD risk factors. This primary prevention program for at risk CAD patients consists of the following components:

- 1) All patients who are 45 years of age or older are identified via the health plan's membership data
- 2) These patients are sent the LM CAD risk assessment survey
- 3) Upon completion of these surveys, patients are identified who are at high risk for the development of coronary artery disease (CAD) as defined by the American Heart Association.
- 4) In order to promote best practice clinical management of these at-risk patients, the identified personal physician of these patients is sent a follow-up LM CAD data collection tool for completion of patient-specific clinical data
- 5) Upon return of this CAD data collection tool back to LM, the physician is sent a one page, patient-specific "best practice" set of recommendations based on the American Cardiology/American Heart Association clinical guidelines.
- 6) This patient-specific CAD data collection tool and recommendation report is then sent to the physician every six months so the physician can longitudinally track the care management progress of his/her at-risk patients for CAD.

Enclosed with this cover letter is a CAD data collection tool for each of the patients in your practice that have been identified as high risk for the development of CAD. We want to thank you beforehand for your timely completion of these clinical data forms and hope they will be helpful in tracking the care of your patients.

Please contact _____ with questions or feedback about the program. We appreciate your support and look forward to a successful program.

Sincerely,

LifeMasters Supported SelfCare, Inc.

Enclosure: CAD Data Collection Tool and



LifeMasters®

Figure 4

LifeMasters® CAD Program – Data Collection Form

Instructions:



Fill in the data collection date

Complete Section I:

Correct the current information and/or supply missing information, as applicable

Complete Section II:

Check the “Yes” or “No” checkboxes for all items as applicable

Complete Section III:

Check the “Yes” or “No” checkboxes for all items as applicable

Date: _____

Section 1 – Patient/Physician Information

Patient Name:		AGE:	DOB:
Height:	Weight:		
Physician Name:			
Physician Address:			
Physician Phone Number:	FAX Number:	Email:	

Section II – Medical History /Risk Factors

	Yes <input type="checkbox"/> No <input type="checkbox"/>		Yes <input type="checkbox"/> No <input type="checkbox"/>
History of MI	Yes <input type="checkbox"/> No <input type="checkbox"/>	Hospitalization for MI in last 12 months	<input type="checkbox"/> <input type="checkbox"/>
History of CABG or angioplasty			<input type="checkbox"/> <input type="checkbox"/>
History of angina pectoris			<input type="checkbox"/> <input type="checkbox"/>
History of positive stress test (ECG stress test or echocardiography stress test)			<input type="checkbox"/> <input type="checkbox"/>
History of diabetes			<input type="checkbox"/> <input type="checkbox"/>
Most recent HbA1c level is $\geq 8\%$			<input type="checkbox"/> <input type="checkbox"/>
History of hypertension	Yes <input type="checkbox"/> No <input type="checkbox"/>	Is hypertension well controlled (BP $\geq 130/85$, if diabetes BP $> 130/80$)	<input type="checkbox"/> <input type="checkbox"/>
History of hyperlipdemia			<input type="checkbox"/> <input type="checkbox"/>
LDL-c within the past 12 months	Yes <input type="checkbox"/> No <input type="checkbox"/>	Is the LDL-c < 100 mg/dL ?	<input type="checkbox"/> <input type="checkbox"/>
Triglycerides within the past 12 months	Yes <input type="checkbox"/> No <input type="checkbox"/>	Is the triglycerides < 200 mg/dL?	<input type="checkbox"/> <input type="checkbox"/>
HDL-c within past 12 months	Yes <input type="checkbox"/> No <input type="checkbox"/>	Is the HDL-c ≥ 40 mg/dL	<input type="checkbox"/> <input type="checkbox"/>
Current smoker			<input type="checkbox"/> <input type="checkbox"/>
If the patient is a current smoker, is smoking cessation counseling given at every clinic appointment			<input type="checkbox"/> <input type="checkbox"/>

Section III – Medication Profile

	Yes <input type="checkbox"/> No <input type="checkbox"/>
Is the patient on antiplatelet therapy?	<input type="checkbox"/> <input type="checkbox"/>
Is the patient on beta blocker therapy (if history of MI present)?	<input type="checkbox"/> <input type="checkbox"/>
Is the patient on statin therapy?	<input type="checkbox"/> <input type="checkbox"/>
Is the patient on nicotinic acid, fibrate or resin therapy	<input type="checkbox"/> <input type="checkbox"/>



Fax the completed form to LifeMasters



Figure 5 LifeMasters® CAD Program Recommendations

LifeMasters®

Report Date: _____ CAD Clinical Recommendations for John Doe (id:17) Based on data collected _____

Past Medical History: (1) MI (within last 12 months), (2) Angina, (3) Diabetes, and (4) Hypertension

These recommendations are intended to assist physicians in clinical decision making by describing a range of generally acceptable approaches for the management, or prevention of CAD.

Indicator	Goal	Goal Met	Recommendations
MI (within last 12 months)	β -blocker therapy initiated	No	<ul style="list-style-type: none">Post Recent MI History of MI within last 12 months. No β-blocker medication reported. The ACC/AHA recommends the initiation of β-blocker therapy.²
Antiplatelet Therapy	Antiplatelet therapy initiated	Yes	<ul style="list-style-type: none">Antiplatelet Therapy Antiplatelet therapy reported. No additional recommendations.
Hypertension	BP < 130/85 (< 130/80 for diabetes)	No	<ul style="list-style-type: none">Hypertension BP \geq 130/85 reported. For uncomplicated hypertension, the JNC VI recommends the use of β-blocker and/or diuretics as first line therapy. As recommended by the ACC/AHA guidelines, for patients with known CAD titrate medication regimen to BP < 130/85 (for diabetic patients, titrate BP to < 130/80). If patient also diagnosed with diabetes or CHF, consider ACE inhibitor medication as first line therapy. If patient has NYHA class II or III CHF, also consider adding β-blocker therapy.⁴
LDL-c	LDL-c < 100 mg/dL	No	<ul style="list-style-type: none">Elevated LDL-c LDL-c level \geq 100 mg/dL reported and patient on statin therapy. Recommend either titrating current medication, adding another lipid lowering medication or changing to alternative therapeutic regimen in order to achieve ACC/AHA recommended LDL-c level of < 100 mg/dL.^{1,2}
Triglycerides	Triglycerides < 200 mg/dL	No	<ul style="list-style-type: none">Elevated Triglycerides Triglycerides level > 200 mg/dL reported. The ACC/AHA recommends gemfibrozil or niacin therapy for patients with HDL-c < 40 mg/dL and triglycerides level > 200 mg/dL, if no contraindications.^{1,2}
HDL-c	HDL-c \geq 40	No	<ul style="list-style-type: none">Low HDL-c HDL-c level < 40 mg/dL reported. Currently on lipid lowering medication. If accompanying triglycerides levels > 200 mg/dL, the ACC/AHA Recommends gemfibrozil or niacin therapy.^{1,2}
Diabetes	HbA1c < 8%	No	<ul style="list-style-type: none">Diabetes HbA1c \geq 8% reported. The ADA recommends a HbA1c goal < 7%. The findings of the DCCT and UKPDS studies indicate that strict blood glucose control will prevent up to 70% of significant, kidney, eye, and neurological complications. These studies also indicate that every percentage point decrease in an individual's HbA1c level there is a 25% reduction in diabetes-related deaths, a 7% reduction in all-cause mortality and an 18% reduction in combined fatal and nonfatal myocardial infarction.³
Current Smoker	Non-smoker	Not Known	<ul style="list-style-type: none">Smoking Cessation No response received. Assess the patient's smoking status and offer appropriate interventions if currently smoking.⁵
Obesity	BMI < 27 Kg/m ²	No	<ul style="list-style-type: none">Regular exercise may reduce the risk of CADRecommend low cholesterol, low fat diet

¹AHA/ACC/ACP-ASIM Guidelines for the Management of Patients with Chronic Unstable Angina and Acute MI (2000)

²National Cholesterol Education Program (NCEP - ATPIII) - 2001

³American Diabetes Association 2001

⁴The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) - 1997

⁵Treating Tobacco Use and Dependence, U.S. Department of Health and Human Services Clinical Guidelines - 2000